68Ga-PSMA-BCH(68Ga-PSMA-BCH) - 药物靶点：PSMA_在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

多肽偶联核素、诊断用放射药物

别名-

靶点

PSMA

作用机制

PSMA调节剂(前列腺癌特异性膜抗原调节剂)

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

北京肿瘤医院（北京大学肿瘤医院）

在研机构

北京肿瘤医院（北京大学肿瘤医院）

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 68Ga-PSMA-BCH 相关的临床结果

登录后查看更多信息

100 项与 68Ga-PSMA-BCH 相关的转化医学

登录后查看更多信息

100 项与 68Ga-PSMA-BCH 相关的专利（医药）

登录后查看更多信息

1

项与 68Ga-PSMA-BCH 相关的文献（医药）

2019-04-01·Bioorganic & medicinal chemistry letters4区 · 医学

Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging

4区 · 医学

Article

作者: Xia, Lei ; Zhu, Hua ; Liu, Teli ; Guo, Xiaoyi ; Xu, Xiaoxia ; Liu, Fei ; Yang, Zhi ; Liu, Chen

Prostate specific membrane antigen (PSMA) is a promising target for the diagnosis and therapy of prostate cancer. In this report, a NOTA-conjugated precursor, NOTA-PSMA (also named PSMA-BCH), was synthesized by peptide synthesizer with the chemical purity over 95%. ⁶⁸Ga-PSMA-BCH was obtained by radiolabeling NOTA-PSMA with ⁶⁸GaCl₃ with >99% radiochemical purity and 59-74 GBq/μmol specific activity. In vitro and in vivo study of ⁶⁸Ga-PSMA-BCH showed high stability, high uptake in PSMA-expressing cells and tumor, fast clearance and low non-target uptake. 22Rv1 tumors were clearly observed in micro-PET images of and showed good retention. Compared with ⁶⁸Ga-PSMA-617, ⁶⁸Ga-PSMA-BCH showed comparable tumor uptake and tumor-background ratios. Indicating ⁶⁸Ga-PSMA-BCH is a promising candidate for prostate cancer imaging and worthy of further clinical investigations.

100 项与 68Ga-PSMA-BCH 相关的药物交易

登录后查看更多信息